-
Related books
European Blue List: European Drug Registrations (Ring Bound Edition)
by Karl Feiden (Ring-bound - Mar 1, 1999)
Excerpt:
... "Bonviva Caelyx Cea-Scan CellCept crixivan Ecokinase epivir Evotopin fareston Gonal-F Hurnalog" ...
More about this bookThe London Lupus Centre, Book of Lupus: A Patients' Guide
by Graham Hughes (Paperback - Dec 15, 2008)
Excerpt:
... "Now there are two new, promising drugs: mycophenolate (Cellcept) and rituximab (Mabthera). Mycophenolate mofetil (MMF or Cellcept)" ...
More about this bookAlive and Fighting: Coping with a Brain Tumor and a Bone Marrow Transplant
by Harry Wolf (Paperback - Dec 2, 2005)
Excerpt:
... "H. Charles Wolf tacrolimus and Cellcept that work well with graft versus host disease. They should" ...
More about this bookThe Patients' Book
by Diane Hartman and Sandra McCray (Paperback - Mar 1, 2000)
Excerpt:
... "was the azathioprine and so told me to switch to CellCept. I had read lots of information about CellCept and knew" ...
More about this bookNierentransplantation
by Rose; Konert, Jrgen; Schabel, Eismann (Paperback - 2004)
Excerpt:
... "die zum Einsatz kom- men knnen (in alphabetischer Reihenfolge): CellCept = Mycophenolatmofetil, MMF Certican = Everolimus Imurek =" ...
More about this bookCellCept, rituxan said to show promise for lupus: the two medications are expected to be particularly useful in the treatment of refractory lupus nephritis.(Rheumatology): ... An article from: Internal Medicine News
by Timothy F. Kirn (Digital - May 22, 2006) - HTML
More about this bookCellCept gaining niche in treating skin disorders: being used as second- or third-line agent: psoriasis, bullous disease treated off label.: An article from: Skin & Allergy News
by Sherry Boschert (Digital - Jun 1, 2005) - HTML
More about this bookCellCept may control severe atopic dermatitis. (Beat Methotrexate, Azathioprine).: An article from: Skin & Allergy News
by Bruce Jancin (Digital - Jul 31, 2005) - HTML
More about this bookPostmarketing CellCept data prompt stronger pregnancy alert.(Women's Health): An article from: Family Practice News
by Elizabeth Mechcatie (Digital - Mar 17, 2009) - HTML
More about this book
medicine: cellcept
cellcept description
Go to trade names and prices
Mycophenolic acid (INN) (pronounced /ˌmaɪkoʊfɨˈnɒlɪk/) or mycophenolate is an immunosuppressant drug used to prevent rejection in organ transplantation. It was initially marketed as the prodrug mycophenolate mofetil (MMF) to improve oral bioavailability. More recently, the salt mycophenolate sodium has also been introduced. Mycophenolic acid is commonly marketed under the trade names CellCept (mycophenolate mofetil; Roche) and myfortic (mycophenolate sodium; Novartis).
Clinical use
Indications
In general, mycophenolate is used for the prevention of organ transplant rejection. Mycophenolate mofetil is indicated for the prevention of organ transplant rejection in adults and renal transplant rejection in children over 2 years; whereas mycophenolate sodium is indicated for the prevention of renal transplant rejection in adults. Mycophenolate sodium has also been used for the prevention of rejection in liver, heart, and/or lung transplants in children >2 years.
An immunosuppressant that has drastically decreased the incidence of acute rejection in solid transplant recipients, mycophenolate is increasingly utilized as a steroid sparing treatment in immune-mediated disorders including immunoglobulin A nephropathy, small vessel vasculitides, and psoriasis.
Its increasing application in treating lupus nephritis has demonstrated more frequent complete response and less frequent complications compared to cyclophosphamide bolus therapy, a regimen with risk of bone marrow suppression, infertility, and malignancy. Further work addressing maintenance therapy demonstrated mycophenolate superior to cyclophosphamide, again in terms of response and side-effects. Walsh et al. even propose that mycophenolate should be considered as a first-line induction therapy for treatment of lupus nephritis in patients without renal dysfunction, suggesting that mycophenolate will be encountered more frequently in medical practice.
Comparison to other agents
Compared with azathioprine it has significantly higher incidence of diarrhoea, and no difference in risk of any of the other side effects. Mycophenolic acid is 15 times more expensive than azathioprine The exact role of mycophenolate vs azathioprine has yet to be conclusively established. In long-term immunosuppression, it may be used to avoid calcineurin inhibitors or steroids.
Potential future uses
Mycophenolate mofetil is beginning to be used in the management of auto-immune disorders such as idiopathic thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE), and pemphigus vulgaris (PV) with success for some patients.
It is also currently being used as a long-term therapy for maintaining remission of C-ANCA positive (Wegener's) granulomatosis. A combination of mycophenolate and ribavirin has been found to stop infection by and replication of dengue virus in vitro.
Adverse effects
Common adverse drug reactions (≥1% of patients) associated with mycophenolate therapy include diarrhea, nausea, vomiting, infections, leukopenia, and/or anemia. Mycophenolate sodium is also commonly associated with fatigue, headache, and/or cough. Intravenous (IV) administration of mycophenolate mofetil is also commonly associated with thrombophlebitis and thrombosis. Infrequent adverse effects (0.1–1% of patients) include esophagitis, gastritis, gastrointestinal tract hemorrhage, and/or invasive cytomegalovirus (CMV) infection. Several cases of pure red cell aplasia (PRCA) have also been reported.
The U.S. Food and Drug Administration (FDA) has issued an alert that patients on mycophenolate mofetil and mycophenolic acid are at increased risk of opportunistic infections, such as activation of latent viral infections, including BK-virus associated nephropathy. In addition the FDA is investigating 16 patients that developed a rare neurological disease while taking the drug. The neurological condition known as progressive multifocal leukoencephalopathy attacks the brain and central nervous system and is usually fatal.
Mycophenolic acid is associated with miscarriage and congenital malformations when used during pregnancy, and should be avoided whenever possible by women trying to conceive.
Pharmacology
Mycophenolate is derived from the fungus Penicillium stoloniferum. Mycophenolate mofetil is metabolised in the liver to the active moiety mycophenolic acid. It inhibits inosine monophosphate dehydrogenase, the enzyme that controls the rate of synthesis of guanine monophosphate in the de novo pathway of purine synthesis used in the proliferation of B and T lymphocytes.
Mycophenolate is potent and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of a three-compound regimen of immunosuppressants, also including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone.
| Name | Information | Price* | Quantity |
| Cellcept 250mg | 100 capsules (mycophenolate mofetil) | $205 | 100 capsules |
| Cellcept 500mg | 50 tablets (mycophenolate mofetil) | $212 | 50 tablets |
| Generic Mycophenolate 250mg | 30 capsule | $55 | 30 capsule |
| Generic Mycophenolate 500mg | 50 tablet | $167 | 50 tablet |
*) Prices related to some of online drugstores. There are only approximate prices. For some of drugs is needed a prescription.
Tags
Keywords related to cellcept
enlon phenolphthalein asacol propofol l dops celexa enovid levocabastine clonidine ademetionine isothipendyl medetomidine copegus cefizox radiogardase elidel haldol phenglutarimide bretylium medrol bretylol anastrozole benzphetamine diatrizoic acid brifentanil haemaccel abelcet saccharic acid benzydamine fentonium cholecalciferol thiamine pyrophosphate dalgan cardrase bimatoprost ms contin methapyrilene tris 2 chloroethyl amine dacetuzumab silibinin mebutamate triflusal vinblastine dicloxacillin phenazopyridine enflurane technetium 99mtc arcitumomab